3-氨基-7-溴-1,2,4-苯并三嗪1-氧化物 | 6298-38-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 中文名称: 3-氨基-7-溴-1,2,4-苯并三嗪1-氧化物
• 英文名称: 3-amino-7-bromo-1,2,4-benzotriazine 1-oxide
• 英文别名: 7-bromo-1-oxido-1,2,4-benzotriazin-1-ium-3-amine
• CAS: 6298-38-0
• 化学式: C₇H₅BrN₄O
• 分子量: 241.047
• InChiKey: ADZAJQYAPJMZSM-UHFFFAOYSA-N

物化性质

• 熔点：
  294-295 °C (decomp)
• 沸点：
  483.8±37.0 °C(Predicted)
• 密度：
  2.09±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  77.3
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933699090

反应信息

• 作为反应物：
  描述：

  3-氨基-7-溴-1,2,4-苯并三嗪1-氧化物 在 盐酸 、 sodium nitrite 作用下， 以 水 为溶剂， 以74.4 %的产率得到7-bromo-1-oxybenzo[1,2,4]triazin-3-ol
  参考文献：
  名称：

  [EN] BENZOTRIAZINE DIOXIDE AND PHARMACEUTICAL COMPOSITION THEREOF
  [FR] DIOXYDE DE BENZOTRIAZINE ET COMPOSITION PHARMACEUTIQUE ASSOCIÉE
  [ZH] 苯并三嗪双氧化物及其药物组合物

  摘要：

  具有以下通式(I)的苯并三嗪双氧化物或其药学上可接受的盐或酯、水合物、溶剂化物或前药，还提供组合物以及治疗癌症的方法。

  公开号：

  WO2023019912A1
• 作为产物：
  描述：

  4'-溴乙酰苯胺 在 盐酸 、 硝酸 、 乙酸酐 作用下， 以 乙醚 、 二氯甲烷 、 水 为溶剂， 反应 7.0h， 生成 3-氨基-7-溴-1,2,4-苯并三嗪1-氧化物
  参考文献：
  名称：

  Discovery and Optimization of Benzotriazine Di-N-Oxides Targeting Replicating and Nonreplicating Mycobacterium tuberculosis

  摘要：

  Compounds bactericidal against both replicating and nonreplicating Mtb may shorten the length of TB treatment regimens by eliminating infections more rapidly. Screening of a panel of antimicrobial and anticancer drug classes that are bioreduced into cytotoxic species revealed that 1,2,4-benzotriazine di-N-oxides (BTOs) are potently bactericidal against replicating and nonreplicating Mtb. Medicinal chemistry optimization, guided by semiempirical molecular orbital calculations, identified a new lead compound (20q) from this series with an MIC of 0.31 mu g/mL against H37Rv and a cytotoxicity (CC50) against Vero cells of 25 mu g/mL. 20q also had equivalent potency against a panel of single-drug resistant strains of Mtb and remarkably selective activity for Mtb over a panel of other pathogenic bacterial strains. 20q was also negative in a L5178Y MOLY assay, indicating low potential for genetic toxicity. These data along with measurements of the physiochemical properties and pharmacokinetic profile demonstrate that BTOs have the potential to be developed into a new class of antitubercular drugs.

  DOI：

  10.1021/jm300123s

文献信息

• A Convenient Synthesis of 3-Amino-1,2,4-benzotriazine 1,4-Dioxide (SR 4233) and Related Compounds via Nucleophilic Aromatic Substitution Between Nitroarenes and Guanidine Base
  作者：Hitomi Suzuki、Takehiko Kawakami

  DOI：10.1055/s-1997-1283

  日期：1997.8

  Reaction of 1-fluoro-2-nitrobenzene or 1,2-dinitrobenzene with guanidine in hot THF followed by treatment with potassium tert-butoxide gave 3-amino-1,2,4-benzotriazine 1-oxide in good yield, which was further oxidized by peracetic acid to afford the title compound.

  1-氟-2-硝基苯或1,2-二硝基苯与胍在热四氢呋喃中反应，随后用叔丁醇钾处理，以良好产率得到3-氨基-1,2,4-苯并三嗪1-氧化物，再经过过氧乙酸氧化，得到目标化合物。
• Vasculostatic agents and methods of use thereof
  申请人：Wrasidlo Wolfgang

  公开号：US20050282814A1

  公开（公告）日：2005-12-22

  Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases, inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.

  提供了用于治疗与血管稳态受损相关的疾病的组合物和方法。发明的方法和组合物可用于治疗各种疾病，包括中风、心肌梗死、癌症、缺血/再灌注损伤、类风湿性关节炎等自身免疫疾病、眼部疾病如视网膜病变或黄斑变性或其他玻璃体视网膜疾病、炎症性疾病、血管渗漏综合征、水肿、移植排斥反应、成人/急性呼吸窘迫综合征（ARDS）等。
• Benzotriazine inhibitors of kinases
  申请人：Noronha Glenn

  公开号：US20050245524A1

  公开（公告）日：2005-11-03

  The invention provides benzotriazine compounds having formula (I). The benzotriazine compounds of the invention are capable of inhibiting kinases, such members of the Src kinase family, and various other specific receptor and non-receptor kinases.

  该发明提供了具有化学式（I）的苯并三唑化合物。该发明的苯并三唑化合物能够抑制激酶，如Src激酶家族成员，以及其他特定的受体和非受体激酶。
• [EN] SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE<br/>[FR] BENZOTRIAZINES ET QUINOXINALINES SUBSTITUÉES COMME INHIBITEURS DE LA P7OS6 KINASE
  申请人：SENTINEL ONCOLOGY LTD

  公开号：WO2010136755A1

  公开（公告）日：2010-12-02

  The invention provides compounds of the formula (1): or salts or tautomers thereof; wherein X1 is N or N+(O ); X2 is N or CH; Q is a C1-3 alkylene group; R1 is selected from hydrogen, C1-4 hydrocarbyl and hydroxy-C2-4 hydrocarbyl; R2, R3 and R4 are the same or different and each is selected from hydrogen, fluorine, chlorine and methyl; Ar1 is an optionally substituted monocyclic 5 or 6-membered aryl or heteroaryl ring containing 0, 1 or 2 heteroatom ring members selected from O, N and S, or a naphthyl ring and Ar2 is an optionally substituted monocyclic 5 or 6-membered heteroaryl ring containing 1, 2 or 3 heteroatom ring members selected from O, N and S. The compounds of formula (1) are inhibitors of p70S6 kinase and are useful in the treatment of proliferative diseases.

  该发明提供了式（1）的化合物或其盐或互变异构体；其中X1为N或N+（O-）；X2为N或CH；Q为C1-3烷基基团；R1从氢、C1-4烃基和羟基-C2-4烃基中选择；R2、R3和R4相同或不同，每个从氢、氟、氯和甲基中选择；Ar1为含有0、1或2个来自O、N和S的杂原子环成员的可选择取代的单环5或6成员芳基或杂芳基环，或者是一个萘环；Ar2为含有1、2或3个来自O、N和S的杂原子环成员的可选择取代的单环5或6成员杂芳基环。式（1）的化合物是p70S6激酶的抑制剂，可用于治疗增殖性疾病。
• [EN] SUBSTITUTED QUINOXALINES AND BENZOTRIAZINE P70S6 KINASE INHIBITORS<br/>[FR] INHIBITEURS DE TYPE QUINOXALINES ET BENZOTRIAZINE SUBSTITUÉES DE LA P70S6 KINASE
  申请人：SENTINEL ONCOLOGY LTD

  公开号：WO2016170163A1

  公开（公告）日：2016-10-27

  The invention provides compounds that inhibit or modulate the activity of p70S6 kinase, the compounds being of the formula (0), or a salt, tautomer or N-oxide thereof; wherein: X1 is N or N+(0-); X2 is N or CH; Q1 is an optionally substituted C1-8 alkylene; Q2 is a bond or an optionally substituted C1-8 alkylene group; R1 is selected from hydrogen and a group Cy1; Cy1 is an optionally substituted 4 to 7 membered monocyclic non-aromatic carbocyclic or heterocyclic group containing 0, 1 or 2 heteroatom ring members selected from O and S and oxidised forms of S; R2, R3 and R4 are the same or different and each is selected from hydrogen, fluorine, chlorine, C1-2 alkyl and C1-2 alkoxy, wherein each C1-2 alkyl and C1-2 alkoxy is optionally substituted with two or more fluorine atoms; Ar1 is an optionally substituted monocyclic 5 or 6-membered aryl or heteroaryl ring containing 0, 1 or 2 heteroatom ring members selected from O, N and S, or a naphthyl ring Ar2 is an optionally substituted bicyclic 8 to 1 1 -membered heteroaryl group containing 1, 2, 3 or 4 heteroatom ring members selected from O, N and S. The compounds are useful in medicine, for example in the treatment of a disease or condition selected from cancers (e.g. triple negative breast cancer, brain tumours and brain metastases arising from non-brain cancers), neurodevelopmental diseases (e.g. Fragile X syndrome) and neurodegenerative diseases.

  该发明提供了抑制或调节p70S6激酶活性的化合物，该化合物的结构如下式（0），或其盐、互变异构体或N-氧化物；其中：X1为N或N+(0-)；X2为N或CH；Q1为可选择取代的C1-8烷基；Q2为键或可选择取代的C1-8烷基基团；R1选自氢和Cy1基团；Cy1为可选择取代的含有0、1或2个来自O和S的杂原子环成员的4到7成员单环非芳香碳环或杂环基团及S的氧化形式；R2、R3和R4相同或不同，每个选自氢、氟、氯、C1-2烷基和C1-2烷氧基，其中每个C1-2烷基和C1-2烷氧基可选择地取代为两个或更多氟原子；Ar1为可选择取代的含有0、1或2个来自O、N和S的杂原子环成员的单环5或6成员芳基或杂芳基环，或一个萘环；Ar2为可选择取代的含有1、2、3或4个来自O、N和S的杂原子环成员的双环8到11成员杂芳基基团。这些化合物在医学上有用，例如在治疗癌症（如三阴性乳腺癌、脑肿瘤和来自非脑部癌症的脑转移瘤）、神经发育疾病（如脆性X综合征）和神经退行性疾病等疾病或病况的治疗中。